All In Biotech

Drug Trial Radar · NCT05353894

Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Apr 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

27

Planned (sponsor's estimate)

Start

May 2, 2022

Primary completion

Nov 30, 2022

Study completion Nov 30, 2022

Sponsor

Lead sponsor
Genoscience PharmaIndustry
Sponsor type
Industry
First posted
Apr 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

GNS561 is a drug used in preliminary phase 1b study for treatment of patients with primary and secondary liver cancer. The formulation used was oral capsule.The objective of this study in healthy volunteers is to compare pharmacokinetics, safety and tolerability of different formulations (tablets and capsules) and dosage (50 and 200mg) of GNS561 after single oral administration in first part and to evaluate the food effect on pharmacokinetics in second part.

Conditions

  • Primary Liver Cancer

Interventions

  • GNS561 oral tablets and capsulesDrug

    Two formulations and Two dosage will be compared

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: from first administration until 29 days
  2. Maximum Plasma Concentration (Cmax)Time frame: Day 1, Day 2, Day 3, Day 4 and Day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Genoscience Pharma

    Marseille, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.